TRACY BATCHELOR
Dr. Batchelor is Chair, Department of Neurology at Brigham and Women’s Hospital, Co-Leader of the Dana-Farber/Harvard Cancer Center Neuro-Oncology Program, and the Martin A. Samuels, M.D. Professor of Neurology at Harvard Medical School. His career has focused on developing novel, small molecule therapeutics for brain cancer. His is the Principal Investigator (PI) of the Harvard P50/SPORE grant, PI of the Harvard/Stanford site in the NCI/U19 Glioblastoma Therapeutics Network.
Check the activity agenda
Friday, March 22, 2024
• Room 1
08:15-10:30
SESSION 1: INTRODUCTION AND CLASSIFICATION
Opening
The 2021 WHO Classification for brain tumors: what is new?
Maximizing resection in glioma surgery: tricks and challenges of iUS and 5-ALA
Advancements in Treating Primary CNS Lymphomas: A Comprehensive Overview
The role of GammaTile therapy for gliomas
Sponsored by Varian:Today's multi-target treatment: How to be efficient with the precision
Discussion
Moderator: Beatriz Sartori (SP)
Moderator: Manoel Antonio de Paiva (Brasil)
Moderator: Camilla Yamada (SP)
Opening
Presenter: Marcos Maldaun (SP)
Presenter: Gustavo Nader Marta (SP)
The 2021 WHO Classification for brain tumors: what is new?
Speaker: Carmen Lucia Penteado Lancellotti (SP)
Maximizing resection in glioma surgery: tricks and challenges of iUS and 5-ALA
Speaker: Francisco Martínez Ricarte (Espanha)
Advancements in Treating Primary CNS Lymphomas: A Comprehensive Overview
Speaker: Tracy Batchelor (Estados Unidos)
The role of GammaTile therapy for gliomas
Speaker: Sujit Prabhu (Estados Unidos)
Sponsored by Varian:Today's multi-target treatment: How to be efficient with the precision
Speaker: Ernesto Roesler (PE)
Discussion
Monday, March 23, 2024
• Room 1
13:30-15:30
SESSION 4: DIFFUSE GLIOMAS
A Critical Overview of Targeted Therapies for Glioma
Translational research for gliomas: future landscapes and emerging paradigm
The role of CAR T cell therapy in neurooncology
What we do know about non-standard of care treatments for gliomas: cannabis, antidepressants, metformin and others
Bevacizumab, is there still a role for antiangiogenics in glioblastoma?
The optimal timing of palliative care in glioma patients
How feasible is surgery in the motor area?
Discussion
Moderator: ícaro Thiago de Carvalho (SP)
A Critical Overview of Targeted Therapies for Glioma
Speaker: Tracy Batchelor (Estados Unidos)
Translational research for gliomas: future landscapes and emerging paradigm
Speaker: Vinay K. Puduvalli (Estados Unidos)
The role of CAR T cell therapy in neurooncology
Speaker: Andreas Hottinger (Suíça)
What we do know about non-standard of care treatments for gliomas: cannabis, antidepressants, metformin and others
Speaker: Yvonne Kew (Estados Unidos)
Bevacizumab, is there still a role for antiangiogenics in glioblastoma?
Speaker: Juan Sepulveda (Espanha)
The optimal timing of palliative care in glioma patients
Speaker: Daniel Neves Forte (SP)
How feasible is surgery in the motor area?
Speaker: Lorenzo Bello (Itália)
Discussion
Promoted by
Organization
Tourism agency
SILVER SPONSOR
BRONZE SPONSOR
SUPPORT SPONSOR
Institutional Support
